Autor der Publikation

Bitte wählen Sie eine Person um die Publikation zuzuordnen

Um zwischen Personen mit demselben Namen zu unterscheiden, wird der akademische Grad und der Titel einer wichtigen Publikation angezeigt. Zudem lassen sich über den Button neben dem Namen einige der Person bereits zugeordnete Publikationen anzeigen.

 

Weitere Publikationen von Autoren mit dem selben Namen

Oligonucleotide array-based comparative genomic hybridization (aCGH) of 90 neuroblastomas reveals aberration patterns closely associated with relapse pattern and outcome., , , , , , , , , und . Genes Chromosomes Cancer, 45 (12): 1130--1142 (Dezember 2006)Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers., , , , , , , , , und 27 andere Autor(en). Clin Cancer Res, 21 (8): 1904-1915 (April 2015)Classification of neuroblastoma patients by published gene-expression markers reveals a low sensitivity for unfavorable courses of MYCN non-amplified disease., , , , , , , , , und 1 andere Autor(en). Cancer Lett, 250 (2): 250--267 (Juni 2007)High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma., , , , , , , , , und 8 andere Autor(en). Clin Cancer Res, 17 (15): 5082--5092 (August 2011)Subclassification and individual survival time prediction from gene expression data of neuroblastoma patients by using CASPAR., , , , , , , , und . Clin Cancer Res, 14 (20): 6590--6601 (Oktober 2008)IT Infrastructure for Merging Data from Different Clinical Trials and Across Independent Research Networks., , , , , , , , , und . MIE, Volume 228 von Studies in Health Technology and Informatics, Seite 287-291. IOS Press, (2016)Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas., , , , , , , , , und 4 andere Autor(en). Genome Biol, 9 (10): R150 (2008)Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers, , , , , , , , , und 27 andere Autor(en). Clinical Cancer Research, (September 2014)Differential expression of neuronal genes defines subtypes of disseminated neuroblastoma with favorable and unfavorable outcome., , , , , , , , , und . Clin Cancer Res, 12 (17): 5118--5128 (September 2006)Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification., , , , , , , , , und 4 andere Autor(en). J Clin Oncol, 24 (31): 5070--5078 (November 2006)